Parkinson's disease (PD) is a chronic, neurodegenerative disorder that mostly affects the motor system. The clinical andbehavioral characteristics of Parkinson's disease include tremor, tonicity, bradykinesia, and gait abnormalities, whereas the pathology is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and the formation of Lewy bodies (LB) in the cytoplasm. Many risk factors, such as α-synuclein aggregation in LB and mitochondrial dysfunction, have been proposed in relation to complex theories about possible PD mechanisms.
GemPharmatech has developed two PD models that can be used for screening, safety evaluation, and efficacy evaluation of therapeutics.
|Strain Name||Strain Type||Description|
|T054329||B6-hSNCA-A53T||Transgenic||Targeting the A53T mutation Loci of SNCA, GemPharmatech has developed the B6- hSNCA A53T model, which can be applied in the screening and safety evaluation of Parkinson's disease (PD) therapies and the research of PD pathophysiology.|
|T053276||B6-Tfam-flox/Slc6a3-Cre||Cas9-CKO||GemPharmatech has developed a Tfam-CKO mouse model that demonstrates decreased TH+ neurons and impaired exercise capacity in the substantia nigra region from 2 to 3 months of age, which is comparable with the clinical phenotype of Parkinson's disease. This model can be used for the screening, safety evaluation, and pathogenesis of PD drugs.|